Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

Francisco Javier Ampudia‑Blasco,1 Irene Romera,2 Bernat Ariño,3 Ramón Gomis4 1Endocrinology and Nutrition Department, Clinic University Hospital Valencia, Valencia, Spain; 2Eli Lilly and Company España, Madrid, Spain; 3Boehringer Ingelheim España, Barcelo...

Full description

Bibliographic Details
Main Authors: Ampudia-Blasco FJ, Romera I, Ariño B, Gomis R
Format: Article
Language:English
Published: Dove Medical Press 2017-01-01
Series:International Journal of General Medicine
Subjects:
cardiovascular
outcome studies
SGLT2 inhibitors
empagliflozin
dapagliflozin
canagliflozin.
Online Access:https://www.dovepress.com/following-the-results-of-the-empa-reg-outcome-trial-with-empagliflozin-peer-reviewed-article-IJGM

Internet

https://www.dovepress.com/following-the-results-of-the-empa-reg-outcome-trial-with-empagliflozin-peer-reviewed-article-IJGM

Similar Items